Cargando…

Aflibercept in the Treatment of Metastatic Colorectal Cancer

Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Tzu-Fei, Lockhart, Albert Craig
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Libertas Academica 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3256978/ https://www.ncbi.nlm.nih.gov/pubmed/22253552 http://dx.doi.org/10.4137/CMO.S7432

Ejemplares similares

Ziv-aflibercept in metastatic colorectal cancer
por: Patel, Anuj, et al.
Publicado: (2013)

Ziv-Aflibercept Use in Metastatic Colorectal Cancer
por: Rodriguez, Mabel
Publicado: (2013)

Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept
por: Dietvorst, Maria H. P., et al.
Publicado: (2013)

Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept
por: Giordano, Guido, et al.
Publicado: (2014)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC)
por: He, Kuifeng, et al.
Publicado: (2012)

Safety of Aflibercept in Metastatic Colorectal Cancer: A Literature Review and Expert Perspective on Clinical and Real-World Data
por: Muro, Kei, et al.
Publicado: (2020)

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
por: Devaux, Madeline, et al.
Publicado: (2019)

Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept
por: de Oliveira Dias, João Rafael, et al.
Publicado: (2016)

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer
por: Denda, Tadamichi, et al.
Publicado: (2019)

Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016)

Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases
por: Alcaide, Julia, et al.
Publicado: (2016)

Exploration of potential prognostic biomarkers in aflibercept plus FOLFIRI in Japanese patients with metastatic colorectal cancer
por: Hamaguchi, Tetsuya, et al.
Publicado: (2019)

Aflibercept with FOLFIRI in Japanese patients with metastatic colorectal cancer: results of a post-marketing surveillance
por: Watanabe, Jun, et al.
Publicado: (2022)

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice
por: Ottaiano, Alessandro, et al.
Publicado: (2019)

Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience
por: Lavacchi, Daniele, et al.
Publicado: (2021)

Efficacy, safety, and cost-effectiveness analysis of aflibercept in metastatic colorectal cancer: A rapid health technology assessment
por: Ge, Pu, et al.
Publicado: (2022)

Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer
por: Yoshino, Takayuki, et al.
Publicado: (2012)

Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer
por: De Souza, Andre, et al.
Publicado: (2015)

A VELOUR post hoc subset analysis: prognostic groups and treatment outcomes in patients with metastatic colorectal cancer treated with aflibercept and FOLFIRI
por: Chau, Ian, et al.
Publicado: (2014)

Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA
por: Ivanova, Jasmina I., et al.
Publicado: (2017)

Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
por: Fernández Montes, Ana, et al.
Publicado: (2019)

Aflibercept for the Treatment of Age-Related Macular Degeneration
por: Trichonas, George, et al.
Publicado: (2013)

A Review of Aflibercept Treatment for Macular Disease
por: Anguita, Rodrigo, et al.
Publicado: (2021)

Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
por: Kim, Jinchul, et al.
Publicado: (2021)

Risk of antiangiogenic adverse events in metastatic colorectal cancer patients receiving aflibercept in combination with chemotherapy: A meta-analysis
por: Ge, Pu, et al.
Publicado: (2023)

Evaluation of efficacy and safety markers in a phase II study of metastatic colorectal cancer treated with aflibercept in the first-line setting
por: Lambrechts, Diether, et al.
Publicado: (2015)

Safety and Effectiveness of Aflibercept + Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study
por: Chau, Ian, et al.
Publicado: (2020)

Treatment-related mortality with aflibercept in cancer patients
por: Tabernero, Josep, et al.
Publicado: (2014)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018)

Chemotherapy and Targeted Agents in the Treatment of Elderly Patients with Metastatic Colorectal Cancer
por: Tuca, Albert, et al.
Publicado: (2020)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

Efficacy and safety of FOLFIRI/aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin-based regimen
por: Martínez-Lago, Nieves, et al.
Publicado: (2022)

Treatment of metastatic colorectal cancer: focus on panitumumab
por: Tay, Rebecca Y, et al.
Publicado: (2015)

Recent developments in the treatment of metastatic colorectal cancer
por: Loree, Jonathan M., et al.
Publicado: (2017)

Molecular Targets for the Treatment of Metastatic Colorectal Cancer
por: Cohen, Romain, et al.
Publicado: (2020)

Oral drugs in the treatment of metastatic colorectal cancer
por: García-Alfonso, Pilar, et al.
Publicado: (2021)

Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept
por: García-Layana, Alfredo, et al.
Publicado: (2015)

Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab
por: Williams, Kerry J, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_nuq6hua5tbr97annp2rhmdqb59